Home
Conditions
Digestive System Neoplasms

Clinical trial condition

Digestive System Neoplasms

Explore clinical trials studying Digestive System Neoplasms. Study availability and eligibility vary by location and protocol.

14,230 public trials 3,233 recruiting studies

Refine in advanced search Browse all conditions

Digestive System Neoplasms trial results

Active, Not Recruiting

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

NCT04522544

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations: Universitätsklinikum Bonn Bonn, Germany

Universitätsklinikum Köln Cologne, Germany

Universitätsklinikum Essen Essen, Germany

Universitätsmedizin Göttingen Göttingen, Germany

View Trial Details

Active, Not Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947

Conditions: Adenocarcinoma, Adnexal Diseases, Bladder Cancer, +58 more
Locations: HonorHealth Research Institute Scottsdale, Arizona, United States

AOA-HOPE Tucson, Arizona, United States

USC Norris Comprehensive Cancer Center Los Angeles, California, United States

HOAG Memorial Hospital Presbyterian Newport, California, United States

View all 14 locations

View Trial Details

Active, Not Recruiting

Screening for Chronic Liver Diseases in General Population

NCT06366425

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +15 more
Locations: CHU de Montpellier Montpellier, France

View Trial Details

Active, Not Recruiting

Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial

NCT04727307

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: CHU Amiens Amiens, France

CHU d'Angers Angers, France

Hôpital Jean Verdier Bondy, France

Hôpital Beaujon Clichy, France

View all 19 locations

View Trial Details

Active, Not Recruiting

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

NCT05843188

Conditions: Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +9 more
Locations: Sunnybrook Odette Cancer Centre Toronto, Ontario, Canada

Princess Margaret Cancer Centre Toronto, Ontario, Canada

View Trial Details

Active, Not Recruiting

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

NCT02151084

Conditions: Biliary Tract Carcinoma, Biliary Tract Diseases, Biliary Tract Neoplasms, +11 more
Locations: Princess Margaret Cancer Centre Toronto, Ontario, Canada

View Trial Details

Active, Not Recruiting

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

NCT05143970

Conditions: Adnexal Diseases, Advanced Solid Tumor, Breast Diseases, +48 more
Locations: Institut Paoli Calmettes Marseille, France

View Trial Details

Active, Not Recruiting

ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

NCT05056896

Conditions: Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +9 more
Locations: Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

NCT04503278

Conditions: Adnexal Diseases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +35 more
Locations: Peter MacCallum Cancer Centre Melbourne, Victoria, Australia

Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin Berlin, Germany

Universitätsklinikum Köln AÖR-Centrum für Integrierte Onkologie (CIO)-Studienzentrum der Klinik I für Innere Medizin (CTU Cologne) Cologne, Germany

Universitätsklinikum Erlangen - Hämatologie & Intrinsische Onkologie - Medizinische Klinik 5 Erlangen, Germany

View Trial Details

Active, Not Recruiting

Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI

NCT07658105

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Digestive System Neoplasms

Digestive System Neoplasms trial results

Related conditions